FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

C Deletionship of Departing Develop(s) to Jesus

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person MADRI JOSEPH A (Last) (First) (Middle) C/O ALEXION PHARMACEUTICALS INC 352 KNOTTER DRIVE					_ AI AI 3. I	ALEXION PHARMACEUTICALS INC [ALXN] 3. Date of Earliest Transaction (Month/Day/Year)									call applicable) Director Officer (give title below)		10% Ow Other (s below)		wner	
						09/16/2013 4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable					
(Street) CHESHIRE CT 06410														ne) X	,					
(City)	(S		(Zip)	n Dori	votiv		ourid	ioo Ao	auirad	Die	nocod o	of or Do	noficia	lly C)wood					
1. Title of Security (Instr. 3) 2. Tra			2. Trans	nsaction h/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr.					or 5. Am 4 and 5) Secur Bener Owne		nt of es ally following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) o (D)	r Price	- 11	Reported Transact (Instr. 3 a	ion(s)			(Instr. 4)	
Common Stock, par value \$.0001 per share 09						09/1			М		30,000	(1) A	\$5.	55	209	,217		D		
Common Stock, par value \$.0001 per share 09/16.				6/2013	2013		S		30,000	(1) D	\$11	(2)	179	179,217		D				
		-	Table II -								osed of, converti			y Ov	vned					
	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	Date, Transact Code (In				6. Date E Expiratio (Month/D	n Date	of Securities		ties ng e Security	De Se	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e C s F llly C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				С	Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	Amount or Number of Shares	ber						
Common Stock	\$5.55	09/16/2013			M			30,000	03/10/20	05	12/10/2014	Common Stock	30,000		\$115	0		D		

Explanation of Responses:

- 1. The transactions reported by this Form 4 are made pursuant to the terms of a sales plan designed to meet the requirements of Rule 10b5-1(c)(1) of the Securities Exchange Act.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$115.00 \$115.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Remarks:

/s/ Joseph Madri

09/18/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.